Understanding the Molecular Basis of Fragile X Syndrome Using Differentiated Mesenchymal Stem Cells by Fazeli, Zahra et al.
85Iran J Child Neurol. Winter 2022 Vol. 16 No. 1
Abstract
Objectives 
Fragile X syndrome (FXS) has been known as the most common cause 
of inherited intellectual disability and autism. This disease results from 
the loss of fragile X mental retardation protein expression due to the 
expansion of CGG repeats located on the 5’ untranslated region of the 
fragile X mental retardation 1 (FMR1) gene. 
Materials & Methods
In the present study, the peripheral blood-mesenchymal stem cells 
(PB-MSCs) of two female full mutation carriers were differentiated 
into neuronal cells by the suppression of bone morphogenesis pathway 
signaling. Then, the expression of genes adjacent to CGG repeats 
expansion, including SLIT and NTRK-like protein 2 (SLITRK2), 
SLIT and NTRK-like protein 4 (SLITRK4), methyl CpG binding 
protein 2 (MECP2), and gamma-aminobutyric acid receptor subunit 
alpha-3 (GABRA3), were evaluated in these cells using SYBR Green 
real-time polymerase chain reaction. 
Results 
The obtained results indicated that the expression of SLITRK2 and 
SLITRK4 were upregulated and downregulated in the neuron-like cells 
differentiated from the PB-MSCs of females with FMR1 full mutation, 
compared to that of the normal females, respectively. Furthermore, 
the expression of MECP2 and GABRA3 genes were observed to be 
related to the phenotypic differences observed in the female FMR1 
full mutation carriers. 
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Conclusion
The observed association of expression of genes located upstream of 
the FMR1 gene with phenotypic differences in the female carriers 
could increase the understanding of novel therapeutic targets for 
patients with mild symptoms of FXS and the patients affected by 
other FMR1-related disorders.
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Introduction
Fragile X syndrome (FXS, OMIM 309550) is 
the most common cause of inherited mental 
retardation that results from the expansion of CGG 
repeats in the 5’ untranslated region (5’ UTR) of 
the fragile X mental retardation 1 (FMR1) gene 
(1). The incidence of FXS has been estimated 
approximately at 1 in 4,000 males and 1 in 8,000 
females (2). Almost 25% of boys and 6% of girls 
affected by FXS will develop autism spectrum 
disorders (ASD); however, only 1-2% of ASD 
patients presented FXS (3-4). Men affected by FXS 
usually exhibit moderate mental retardation and 
often have physical and behavioral characteristics 
(5). Females with FMR1 gene full mutation showed 
intelligence quotient scores within the range of 
normal to less than 70 points (6). Furthermore, 
failure in short-term memory, executive function, 
and visual memory and language impairments are 
very common in individuals with FXS (7-10). 
A genetically-engineered mouse model for FXS 
did not show characteristics similar to methylation 
and gene silencing of the FMR1 gene in humans 
(11). Epigenetic mechanisms in humans and mice 
are different. Therefore, the mice was not suitable 
models to study FMR1 epigenetic mechanisms. 
Furthermore, the differences between mouse and 
human brain structures reflected the challenges 
in understanding the molecular mechanisms of 
abnormal brain development and function in FXS 
patients. Studies indicated that brain development 
in humans required more time than in mice. The 
human brain is also very dependent on interneurons 
and astrocytes. Clear differences were observed in 
the nervous system of mouse models and patients 
with FXS. For example, the development of human 
interneurons occurs over a prolonged period and 
requires the integration of unique mechanisms to 
generate numerous interneurons (12-13). The study 
of FXS epigenetic mechanisms in humans could 
provide a better understanding of the disease. 
Numerous studies have been performed on 
embryonic stem (ES) and induced pluripotent stem 
(iPS) cells derived from patients with FXS. These 
cells could be very beneficial to study molecular 
mechanisms and development stages of diseases. 
For example, iPS cells can be used as a model to 
study FMR1 gene transcription switching from 
active to inactive status during differentiation. 
Although human iPS and ES cells were very 
beneficial, there were some limitations on the use 
of these cells. The application of ES cells isolated 
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from human embryos was associated with ethical 
problems, and the successful generation of iPS 
cells from somatic cells was dependent on the used 
method (14). 
Recently, the identification and isolation of stem 
cells derived from different organs have provided 
a new cellular model to study the molecular 
mechanisms of different diseases. However, it is 
not possible to isolate stem cells from some tissues, 
including the central nervous system. Stem cells 
derived from other tissues have been known to have 
differentiation ability into the cells of other tissues. 
They could provide a new source of cells to study 
in vitro. Recent studies have demonstrated that 
mesenchymal stem cells (MSCs) can differentiate 
into different cell types, including neuronal cells 
(15). In the present study, peripheral blood-
mesenchymal stem cells (PB-MSCs) were used 
to differentiate into neuron-like cells. Although 
bone marrow is the main source of MSCs, its cell 
separation technique is an invasive procedure. The 
MSCs could be isolated from peripheral blood by a 
non-invasive method as previously published (15). 
The product of the FMR1 gene, fragile X mental 
retardation protein (FMRP), plays an important 
role in the regulation of the translation of the 
dendritic messenger ribonucleic acid (mRNA) 
molecules in response to the activation of synapses 
(16-17), indicating that the lack of this protein was 
associated with mental retardation in males with 
FXS (18). Although the molecular mechanism of 
FXS has been revealed to be the expansion of CGG 
repeats located on the 5’ UTR of the FMR1 gene and 
its abnormal methylation, some studies indicated 
that the hyper-methylation of the FMR1 gene could 
directly or indirectly affect the expression of some 
of its downstream genes (19). For increasing the 
understanding of FXS etiology, the expression of 
four genes adjacent to the CGG repeats expansion 
of the FMR1 gene (i.e., SLIT and NTRK-like 
protein 2 (SLITRK2), SLIT and NTRK-like 
protein 4 (SLITRK4), gamma-aminobutyric acid 
receptor subunit alpha-3 (GABRA3), and methyl 
CpG binding protein 2 (MECP2) were evaluated 
in the females with FMR1 gene full mutation and 
different phenotypic characteristics.  
Materials & Methods
Patients 
In this study, 20 ml peripheral blood samples were 
obtained from two females with full mutation 
referred to Kariminejad & Najmabadi Pathology 
and Genetics Center, Tehran, Iran (named NF and 
MF, respectively), as well as a normal female with 
a normal allele. The expansion of CGG repeats 
upstream of the FMR1 gene was determined using 
triplet-primed polymerase chain reaction (TP 
PCR), as confirmed by AmplideX FMR1 PCR 
kit  (Asuragen, Austin, TX, USA) and Southern 
blotting. 
Methylation Analysis
The methylation pattern of CGG repeats expansion 
upstream of the FMR1 gene was determined by 
methylation-specific polymerase chain reaction 
(MS PCR) followed by capillary electrophoresis. At 
first, sodium bisulfite modification was performed 
on genomic deoxyribonucleic acid (DNA) using 
EpiTect® Bisulfite (Qiagen, UK). Then, the 
modified DNA was subject to MS PCR using 
primers specific for methylated (Met PCR) and 
unmethylated PCR (non-Met PCR). The primers 
were as previously described (20). The PCR was 
prepared in a final volume of 25 μl containing 0.8 
mM deoxyribonucleotide triphosphate (Qiagen, 
UK), 1X PCR buffer with 2.5 mM magnesium 
chloride, 1.5x Q-Solution (Qiagen, UK), 100 ng 
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modified DNA, 0.4 μM of forward and reverse 
primers, and 2.5 U HotStarTaq DNA polymerase 
(Qiagen, UK). The PCR conditions included one 
initial denaturation at 95 °C for 10 minutes, 14 
cycles (98 °C for 1 minute, 74.2 °C (Met PCR) or 
68.1 °C (non-Met PCR) for 1 minute, and 72 °C 
for 2 minutes with 0.5 °C/s ramp rate; reducing 
the annealing temperature by 0.5 °C each cycle), 
19 cycles (98 °C for 1 minute, 67.2 °C (Met 
PCR) or 61.1 °C (non-Met PCR) for 1 minute, 
and 72 °C for 2 minutes with 0.5 °C/s ramp rate), 
and final extension at 72 °C for 10 minutes. The 
MS PCR products were resolved by capillary 
electrophoresis. Then, electropherograms were 
analyzed with Peak Scanner Software (version 2.0 
; Applied Biosystems, USA).
Expression Analysis
In this protocol, the bone morphogenesis pathway 
in MSCs was suppressed through Noggin treatment.
The neuronal-like cells obtained from the 
differentiation of PB-MSCs were used to investigate 
the expression of genes adjacent to the CGG repeat 
expansion of the FMR1 gene (i.e., SLITRK2, 
SLITRK4, GABRA3, and MECP2) in females 
with full mutation and different presentation 
of clinical symptoms. The selected genes were 
located at Xq28 and Xq27. The previous studies 
indicated that these genes play an important role in 
the development of the nervous system. 
For this purpose, Total RNA was extracted from 
cell cultures using a Total RNA purification 
kit (Jena Bioscience, Germany). Then, 
complementary deoxyribonucleic acid (cDNA) 
was synthesized by RevertAid First Strand 
cDNA Synthesis kit (Thermo Scientific, USA) 
with Random Hexamer Primers. Real-time PCR 
was performed according to the manufacturer’s 
protocol using RealQ Plus Master Mix Green 
(Ampliqon, Denmark). The expression of target 
genes, including SLITRK2, SLITRK4, GABRA3, 
and MECP2, was detected by the SYBR Green 
system and normalized with Heat Shock Protein 
90 Alpha Family Class B Member 1, HSP90AB1, 
expression. The PCR primers were as follows: 
SLITRK2: 5-TGCAGTCATTCAGGAAGGTG-3 













Then, the relative expression level of each gene 
was determined by the Pfaffl method (25).  
Results
Patient’s Characterization
The present study was performed on a female with 
a normal allele and two females with FMR1 full 
mutation. The females who were carriers of FMR1 
full mutation showed different phenotypes. One of 
them presented a normal phenotype; nevertheless, 
the other female showed the symptoms of FXS, 
including mental retardation, learning disability, 
autism, attention deficits, hyperactivity, attentional 
problems, poor eye contact, obsessional interests or 
behaviors, shyness or social anxiety, and prominent 
or large ears. 
Assessment of FMR1 Triplet Repeat Region
The TP PCR followed by capillary electrophoresis 
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analysis showed the presence of two normal alleles 
in the female control. In contrast, a full mutation 
allele was observed in the TP-PCR products of 
two other samples (NF and MF). AmplideX FMR1 
PCR kit and Southern blot analysis also confirmed 
the presence of a normal allele and a full mutation 
allele in these two samples. The MS PCR of the 
FMR1 triplet repeat region showed that the normal 
allele was un-methylated; nonetheless, the full 
mutation allele was methylated in the studied 
carrier females. 
Expression Analysis of FMR1 Flanking Genes
The results obtained from real-time PCR indicated 
that the expression of SLITRK2 upregulated in the 
neuronal cells differentiated from the PB-MSCs of 
females with the full mutation allele of the FMR1 
gene regardless of their phenotype. In contrast, 
the downregulation of SLITRK4 expression was 
detected in these cells. No difference of MECP2 
expression was observed in the neuronal-like cells 
of the normal female with full mutation allele of 
the FMR1 gene, compared to those of the female 
with the normal FMR1 allele; nevertheless, 
MECP2 expression increased in the neuronal-like 
cells of mental retardation female with the full 
mutation (Figure 1). Although the upregulation of 
the GABRA3 gene was observed in the neuronal-
like cells of the normal female with the full 
mutation allele, its expression was decreased in the 
neuronal-like cells of the mental retardation female 
with the full mutation of FMR1 (Figure 2).
Figure 1. Expression Level of Genes Adjacent to the FMR1 Gene, Including SLITRK2, SLITRK4, and MECP2, in the Neuronal-like Cells of Female 
Carriers of FMR1 Full Mutation. NF; Normal female with full mutation, MF; Mental retardation female with full mutation, NN; Normal female with 
normal allele of the FMR1 gene
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Discussion
Among the heterogeneous group of 
neurodevelopmental disorders, FXS is an excellent 
model to study the molecular mechanisms 
of synaptic function that can cause cognitive 
impairment, autism, and behavioral disorders in 
the affected patients (25). The study of targeted 
therapies to correct synaptic changes can reveal the 
new treatment approach for not only FXS patients 
but also other types of neurodevelopmental diseases 
(26-27). In the present study, the relationship 
between the methylation patterns of CGG repeats 
located upstream of the FMR1 gene and genes 
adjacent to FMR1 was investigated in the neuron-
like cells differentiated from the PB-MSCs of 
two females carrying FMR1 full mutation with 
different phenotypes. 
Previous studies indicated that the abnormal 
methylation in the FMR1 promoter region alleles 
containing CGG repeat expansion occurs in 
patients with FXS (28). The most severe phenotype 
of disease was observed in males that all alleles 
of this locus were methylated in all their cells, 
resulting in no expression of FMR1 mRNA (29). 
Tassone et al. reported significant levels of FMR1 
mRNA expression in men with a methylated FMR1 
full mutation allele (30). However, no detectable 
levels of FMR1 mRNA were noticed for some 
males with an unmethylated full mutation allele 
of FMR1. These individuals presented phenotypic 
symptoms similar to males with methylated full 
mutation allele (29). 
The results obtained from some studies suggested 
that there were three types of methylation 
mosaicism at the FMR1 gene, including mosaicism 
among the cells of an individual, mosaicism at 
CpG sites within a gene, or mosaicism between the 
two strands of a single DNA molecule (29). In the 
present study, the abnormal allele of both females 
with full mutation was methylated; nonetheless, 
they showed different phenotypes. The methylation 
mosaicism could explain the observed phenotypic 
differences. These females with full mutation 
allele of the FMR1 gene also showed different 
Figure 2. Expression Level of the GABRA3 Gene Located Adjacent to Expansion of CGG Repeats of the FMR1 Gene in the Neuronal-like Cells 
of Female Carriers of FMR1 Full Mutation. NF; Normal female with full mutation, MF; Mental retardation female with full mutation, NN; Normal 
female with normal allele of the FMR1 gene
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expression patterns of genes adjacent to the FMR1 
gene, compared to the normal female carrying the 
normal allele.
The expression analysis of SLITRK2 and SLITRK4 
indicated that SLITRK2 was overexpressed in the 
differentiated neuronal-like cells of females with 
FMR1 full mutation; however, the expression of 
SLITRK4 decreased in these cells, compared to 
those of the female with the normal allele. Marteyn 
et al. demonstrated that a stable knockdown of 
SLITRK4 and SLITRK2 genes in the neurons of 
wild-type cultures was associated with the induction 
of neurite formation (21). In contrast, the transient 
expression of SLITRK2 and SLITRK4 was 
accompanied by the inhibition of neurite outgrowth 
(31). The SLITRK2 and SLITRK4 were identified 
as the regulators of neurite outgrowth (32). Some 
studies suggested SLITRK2 as a candidate gene of 
bipolar disorder (33). Therefore, the upregulation 
of SLITRK4, along with the downregulation of 
SLITRK2, in the neuronal-like cells generated 
from females with FMR1 full mutation could be 
proposed as the protective mechanism against the 
development of psychiatric disorders, including 
bipolar disorder, in individuals carrying the full 
mutation of FMR1. 
In the present study, the overexpression of the 
MECP2 gene was observed in the neuronal-like 
cells differentiated from the PB-MSCs of mental 
retardation female carrying FMR1 full mutation 
allele; nonetheless, MECP2 gene expression 
showed no difference in the normal female with 
FMR1 full mutation, compared to that of the 
female carrying the normal allele. The mental 
retardation phenotype observed, along with the 
increased expression of MECP2, is consistent with 
the previous observations. The study of MECP2-
null mice indicated that loss of MECP2 damaged 
the learning and memory through the reduction 
of synaptic plasticity and spontaneous activity 
of neurons (34-36). Synaptic defects were also 
reported in transgenic mice that overexpressed 
MECP2, indicating that the regulation of MECP2 
expression level is required for the maturation of 
neurons (37). The activation of immature neurons 
was dependent on the induction of a large number of 
genes contributing to the maturation of developing 
synapses. The MECP2 plays an important role in 
controlling the expression of these genes, including 
Brain Derived Neurotrophic Factor (BDNF), 
Inhibitor of differentiation/DNA binding (ID1), 
Early Growth Response 2 (EGR2), and JUNB (38).
The expression of the GABRA3 gene was also 
investigated in the present study. The results 
obtained from real-time PCR presented that 
the GABRA3 gene was overexpressed in the 
neuronal-like cells of normal females with FMR1 
full mutation; however, the reduction of GABRA3 
expression was observed in the neuronal-like cells 
of the mental retardation female carrying the full 
mutation, compared to that of the normal female. 
Previous studies indicated that the lack of FMRP 
increased the degradation of gamma-aminobutyric 
acid (GABA) receptor subunits, leading to the 
electrophysiological and molecular defects of the 
GABAergic system (38-39). The level of the mRNA 
expression of seven GABA receptor subunits (i.e., 
α1, α3, α4, β1, β2, γ1, and γ2) reduced in the 
cortex of FMR1 knockout mice (39). Furthermore, 
the downregulation of the GABRA3 gene was 
observed in the cortex of patients with autism 
(40). Some studies revealed that dysfunction of 
GABA receptors is involved in the manifestation 
of clinical symptoms, including depression and 
problems with learning, memory, and behavioral 
phenotype of patients with FXS (41). The results 
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of the current study about the downregulation of 
GABRA3 gene expression in the neuronal-like 
cells obtained from the mental retardation female 
with full mutation allele are consistent with the 
results of previous studies.
The activation of GABA receptors containing 
subunits α2 and/or α3 has also been demonstrated 
to involve in the maturation and differentiation of 
neurons (42), and they showed high expression in 
the neuronal synapses of the brain areas affecting 
anxiety (43). Although other subunits of GABA 
receptors were not investigated, the observation 
of GABRA3 (subunit α3) overexpression in the 
neuronal-like cells from the normal female with 
FMR1 full mutation indicated that the upregulation 
of GABRA3 plays a role as a compensatory 
mechanism in the expression changes of other 
GABA receptor subunits.
In Conclusion
the expression of SLITRK2, SLITRK4, MECP2, 
and GABRA3 was observed to be associated 
with the phenotypic characteristics of females 
carrying the full mutation. The obtained results 
could play an important role in the understanding 
of novel therapeutic targets for patients with mild 
symptoms of FXS and patients affected by other 
FMR1-related disorders.
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